期刊文献+

注射用重组人肿瘤坏死因子受体突变体-Fc融合蛋白对中国健康志愿者血浆中肿瘤坏死因子-α浓度水平的影响

Effects of recombinant fusion protein of human tumor necrosis factor receptor mutant and Fc fragment for injection on the plasma concentration of tumor necrosis factor-α in Chinese healthy volunteers
原文传递
导出
摘要 目的研究不同剂量重组人肿瘤坏死因子受体突变体-Fc融合蛋白[rhTNFR(m):Fc]单次皮下给药对中国健康志愿者血浆中肿瘤坏死因子-α(TNF-α)表达水平的影响。方法研究纳入56例健康成年志愿者,分为6个剂量组,分别腹部皮下注射rhTNFR(m):Fc 10,20,35,50,65,75 mg,测定给药前(0 h),给药后4,48,96,168,216,264,312,384,480 h的血浆中游离TNF-α和总TNF-α的浓度。结果单次给药0~264 h后,各个剂量组志愿者体内游离TNF-α和总TNF-α浓度均出现了显著升高;在给药264~480 h后,血浆中游离TNF-α和总TNF-α浓度逐渐下降;给药后480 h,游离TNF-α浓度几乎降至正常。在10~75 mg剂量内,血浆中游离TNF-α和总TNF-α在体内的暴露量(Cmax)与rhTNFR(m):Fc的剂量之间无明显的线性相关性。结论中国健康志愿者单次给予rhTNFR(m):Fc后,可引起血浆中游离TNF-α和总TNF-α水平的升高,因此,血浆中游离TNF-α和总TNF-α水平可能并不适合作为该类药物的药效学评价指标。 Objective To access the effects of different doses of recombinant fusion protein of human tumor necrosis factor receptor mutant and Fc fragment [rhTNFR( m) : Fc] after a single subcutaneous injection on the plasma concentration of tumor necrosis factor-α( TNF-α) in Chinese healthy volunteers. Methods A total of 56 healthy Chinese volunteers were randomly divided into 6 groups to receive a single injection of 10,20,35,65,75 mg of rhTNFR( m) : Fc. The plasma concentrations of TNF-α and total TNF-α were determined at 1 h pre-dose and at 4,48,96,168,216,264,312,384,480 h post-dose.Results After administration of rhTNFR( m) : Fc at 0-264 h,the plasma concentrations of free TNF-α and total TNF-α increased significantly in the each group. At 264-480 h post-dose,the concentration of them began to decrease, and at 480 h the concentration of free TNF-α almostly decreased to normal levels. In the dose range of10-75 mg,the exposure of free TNF-α and total TNF-α( Cmax) had no significant correlation with the dose of rhTNFR( m) : Fc. Conclusion After giving the single dose of rhTNFR( m) : Fc,there was an increase of free and total TNF-α plasma concentration in Chinese healthy volunteers. As a result,the plasma concentration of free and total TNF-α may not be a suitable pharmacodynamic evaluation index.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2018年第3期312-315,326,共5页 The Chinese Journal of Clinical Pharmacology
关键词 重组人肿瘤坏死因子受体突变体-Fc融合蛋白 肿瘤坏死因子-Α 依那西普 recombinant fusion protein of human tumor necrosis factor receptor mutant and Fc fragment tumornecrosis factor - α etanercept
  • 相关文献

参考文献2

二级参考文献20

  • 1Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer[J]. Irnmunol Rev , 2011, 244:9 - 28.
  • 2Faustman DL, Davis M. TNF receptor2 and disease: autoimmunity and regenerative medicine[J]. Front Immunol, 2013,4:47~.
  • 3Burmester GR, Kivitz A J, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial [ J ]. Ann Rheum Dis, 2014,18 : 1 - 8.
  • 4Thorne C, Bensen WG, Choquette D, et al. Effectiveness and safe- ty of infliximab in rheumatoid arthritis: Analysis from a Canadian multicentre prospective observational, re~stry[ J]. Arthritis Care Res ( Hoboken), 2014,26 : 1 - 47.
  • 5Shen L, Lu G, Dong N, et al. Von Willebrand factor, ADAMTS13activity, TNF -α and their relationships in patients with chronic kidney disease[ J]. Exp Ther Med, 2012,3:530 - 534.
  • 6Wing MR, Yang W, Teal V, et al. Race modifies the association between adiposity and inflammation in patients with chronic kidney disease: Findings from the chronic renal insufficiency cohort study [ J]. Obesity (Silver Spring), 2014,22 : 1359 - 1366.
  • 7Bhargava R, Ahmann C J, Andres - Hemando A , et al. Acute lung injury and acute kidney injury are established by four hours in ex- perimental sepsis and are improved with pro, but not post, sepsis administration of TNF - ct antibodies [ J ]. PLoS One, 2013,8 : e79037.
  • 8Arican O, Aeal M, Sasmas S, et al. Serum levels of TNF - alpha, TNF-gamma, IL-6, IL -8, IL - 12, IL - 17, and IL - 18 in patients with active psoriasis and correlation with disease severity [ J ]. Mediators lnlamm, 2005,2005:273 - 279.
  • 9Armesto S, Coto - Segura P, Mayorga J, et al. Efficacy of adali- mumab in the treatment of moderate - to - severe psoriasis : A retro- spective study of 100 patients in daily practice[ EB/OL]. http:// www. ncbi. nlm. nih. gov/pnbmed/24552591, 2014 -02 -20.
  • 10Deventer SV. IBD : emerging therapies [ M ]. AGA postgraduate course syllabus, 2000:239 - 251.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部